Humira / Mabura (adalimumab) 40 mg, India Humira (adalimumab) is used for moderate to severe active rheumatoid arthritis in adults, alone or with methotrexate. International medicine delivery. Contact +380996042415.

Indications

Adults

- moderate and severe active rheumatoid arthritis (in monotherapy or in combination with methotrexate or other basic anti-inflammatory drugs). In combination with methotrexate, Humira reduces the rate of progression of joint damage (according to radiographic studies) and improves functional activity;

- active psoriatic arthritis (in monotherapy or in combination with methotrexate or other basic anti-inflammatory drugs);

- active ankylosing spondylitis;

- Crohn's disease (moderate or severe): with an inadequate response to traditional therapy, as well as with intolerance or contraindications to traditional therapy; in case of ineffectiveness (or decreased effectiveness) or intolerance of infliximab;

- chronic plaque psoriasis (moderate to severe), when systemic therapy or phototherapy is indicated and when other options for systemic therapy are not optimal;

- moderate to severe ulcerative colitis with an inadequate response to traditional therapy, including corticosteroids and/or 6-mercaptopurine or azathioprine, as well as with intolerance or contraindications to traditional therapy;

- axial spondyloarthritis without radiologically confirmed ankylosing spondylitis, but in the presence of objective signs of inflammation based on an increased level of C-reactive protein and/or MRI data, in the absence of an adequate response to treatment with NSAIDs or their intolerance;

- active moderate or severe hidradenitis suppurativa in the absence of an adequate response to standard sy

stem therapy.